graduate at Biomedicina from Universidade Federal do Pará (1983), master's at Microbiology from Universidade Federal de Minas Gerais (1991) and ph.d. at Microbiology from Universidade Federal de São Paulo (1998). Has experience in Parasitology, focusing on Parasitology, acting on the following subjects: malaria, plasmodium vivax, msp-1, ama-1 and msp1. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Inmunización pionera |
| Pioneering immunization |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Plasmodium vivax is the second most prevalent species causing malaria in the world. Recent data estimated 132-391 million cases annually. The relative inefficiency of the measures of control currently used demands the development of new strategies for prevention such as vaccines, new drugs and insecticides. In last the 15 years, studies aimed at the development of a recombinant vaccine ag…
A consortium composed by Universidad Peruana Cayetano Heredia, Universidade de São Paulo, Istituto Superiore di Sanità, Université Catholique de Louvain and Medical Research Council Unit aims to contribute for malaria elimination in the Amazon Region. For this, standardized serosurveillance tools will be developed to accurately monitor short and long-term changes in the Plasmodium vivax t…
Malaria is considered one of the priority areas for research and vaccine development. Plasmodium vivax is the most world-widely distributed and the most prevalent specie in America. Attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. The most advanced clinical trials performed with P. vivax vaccine …
(Only some records are available in English at this moment)
Malaria is a disease that threatens public health on a global scale, and in this context,the Amazon region is strongly affected. Several articles describe the resistance of Anopheles mosquitoes to insecticides and drugs used for this disease, generating a global concern. In this scenery, the development of a vaccine against Plasmodium vivax has been considered an efficient alternative. Ho…
Malaria is considered a serious problem of public health, which can cause severe forms and lead to death, mainly among children under 5 years of age living in Sub-Saharan Africa. In America, an infection caused by Plasmodium vivax represents 74.1% of cases, currently, according to the Pan American Health Organization. Due to the increase in drug and insecticide resistance, the development…
The search for an effective vaccine against malaria caused by Plasmodium vivax is one of the main goals of global research and will likely require a product that includes several antigens from the parasite cycle. To achieve this goal, we propose to develop a multi-antigen and multi-stage vaccine capable of preventing infection and / or clinical manifestations of malaria vivax. Thus, we pr…
Malaria is a serious public health problem worldwide, causing in 2016 about 216 million cases of the disease, mostly concentrated in the tropical Africa region. In Brazil, malaria cases are also alarming, with approximately 200 thousand cases registered in 2017, of which 85% were caused by the species Plasmodium vivax. The main goal of our research group is the development of a recombinan…
(Only some records are available in English at this moment)
Plasmodium vivax is the most common species of malaria outside the African continent. The development of an efficacious vaccine would contribute greatly to control of disease transmission. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (PvCSP), we demonstrated that it is possible to elicit strong antibody-mediated immune respon…
Plasmodium vivax is the most world-widely distributed and the most prevalent specie in America. Vaccine development to P. vivax is considered a priority on the global program for the eradication of malaria. In our process linked entitled "Generation of chimeric recombinant proteins for vaccine development against Plasmodium vivax", we hypothesized that an effective vaccine formulation for…
| 1 / 1 | Ongoing research grants |
| 10 / 5 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 15 / 8 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 29 / 17 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID